DEA Eyes Bulk Production of Psilocybin and Fentanyl—Wait, What?

2026-06523 — Designation of P2P Methyl Glycidic Acid as a List I Chemical

Starting May 4, 2026, anyone handling P2P methyl glycidic acid—a key chemical used to make illegal drugs like methamphetamine—must follow new government rules and register with the DEA. This means all transactions, big or small, will be closely watched to stop illegal drug production. Businesses dealing with this chemical should act fast to stay legal and avoid penalties.

2026-06521 — Importer of Controlled Substances Application: Lipomed/LGC Standards

Lipomed/LGC Standards wants to become an official importer of certain controlled substances, like 3-Fluoro-N-methylcathinone. This means companies involved with these drugs can comment or ask for a hearing by May 4, 2026. If approved, it could impact how these substances enter the U.S., but no direct costs are mentioned yet.

2026-06051 — Importer of Controlled Substances Application: Usona Institute

Usona Institute wants to become an official importer of some powerful controlled substances like mescaline and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 29, 2026. This move could impact research and medical use, with no direct cost changes announced yet.

2026-05618 — Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I

Starting April 22, 2026, the DEA is putting 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it’s now officially a highly controlled substance with strict rules. This affects anyone who makes, sells, studies, or even possesses 3-MeO-PCP, who will face serious legal consequences. This move helps the U.S. follow international drug laws and keeps communities safer.

2026-05486 — Exempt Chemical Preparations Under the Controlled Substances Act

The Drug Enforcement Administration (DEA) just updated which chemical mixes are officially exempt from strict drug rules between September 2024 and December 2025. Companies and labs using these chemicals should check the new list to see if their products are approved or denied. You’ve got until May 19, 2026, to share your thoughts, and no extra fees are involved—just a quick review and comment if you want!

2026-05482 — Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments

If you order Schedule I or II drugs using DEA Form 222, this update clears up who can sign and manage the form—only registrants, their partners, or officers can do it. It also removes old rules about the old triplicate form, making things simpler and clearer. These fixes don’t change any big rules and take effect on March 20, 2026, so no extra costs or hassles ahead!

Previous: 2026-05911 — Notice Pursuant to the National Cooperative Research and Production Act of 1993-R Consortium, Inc.

R Consortium, a group of companies working together on research, announced that Oracle, Google, and Genentech have left the team. This update keeps the group’s special legal protections in place and lets others still join. No money changes or new projects were mentioned, and the group will keep sharing updates as members come and go.

Next: 2026-05913 — Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications; Correction

The FDA fixed a mistake about pulling approvals for 72 generic drug applications. One drug, a valproic acid capsule from Upsher-Smith Laboratories, won’t lose its approval because the company asked to keep it. This means the drug stays available, and the change took effect before October 23, 2025.